Review Article
Hypofractionated External-Beam Radiotherapy for Prostate Cancer
Table 2
Prospective trials of hypofractionated external-beam radiotherapy (5 fractions).
| | Author | No. of patients | Type of study | Patient
characteristics
NCCN risk group | HYPO FX
Total dose(Gy)/fractional dose(Gy)
| Median
follow up
(months) | PSA control
| Late GU toxicity
| Late GI toxicity |
| |
Madsen et al. [53, 54] | 40 | Phase I/II | Low risk | 33.5/6.7 | 60 | 93%*at 5 years | 12.5%
2.5% | Gr-2
Gr-3 | 12.5%
0% | Gr-2
Gr-3 |
| | Tang et al. [55] | 30 | Phase I/II | Low risk
| 35/7 | 12 | — | 13%
0% | Gr-2
Gr-3 | 7%
0% | Gr-2
Gr-3 |
| | King et al. [56, 57] | 67 | Phase II | Low risk | 36.25/7.25 | 32 | 94%*at 4 years | 3%
5% | Gr-2
Gr-3 | 2%
0% | Gr-2
Gr-3 |
| | McBride et al. [58] | 45 | Phase I | Low risk | 36.25/7.25
37.5/7.5 | 44.5 | 98%* at 3 years | 17%
2% | Gr-2
Gr-3 | 7%
5% | Gr-2
Gr-3 |
| | Boike et al. [59] | 45 | Phase I | Low-Intermediate risk | 45/9
47.5/9.5
50/10 | 12–30 | 100%* | 9%
4% | Gr-2
Gr-3 | 4%
0%
2% | Gr-2
Gr-3
Gr-4 | | | | | | | | | Late toxicity | Late toxicity | | | | | | | | | after 90 days | after 90 days |
|
|
No.: Number, HYPO FX: hypofractionation, STD FX: standard, Gy: Gray, FX: fractionation, *: by Phoenix definition, NS: not significantly different, GS: Gleason’s score.
|
